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SUMMARY
Excessive and unresolved neuroinflammation is a key component of the pathological cascade in 
brain injuries such as ischemic stroke. Here, we report that TRIM9, a brain-specific tripartite motif 
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(TRIM) protein, was highly expressed in the peri-infarct areas shortly after ischemic insults in 
mice, but expression was decreased in aged mice, which are known to have increased 
neuroinflammation after stroke. Mechanistically, TRIM9 sequestered β-transducin repeat-
containing protein (β-TrCP) from the Skp-Cullin-F-box ubiquitin ligase complex, blocking IκBα 
degradation and thereby dampening nuclear factor κB (NF-κB)-dependent proinflammatory 
mediator production and immune cell infiltration to limit neuroinflammation. Consequently, 
Trim9-deficient mice were highly vulnerable to ischemia, manifesting uncontrolled 
neuroinflammation and exacerbated neuropathological outcomes. Systemic administration of a 
recombinant TRIM9 adeno-associated virus that drove brain-wide TRIM9 expression effectively 
resolved neuroinflammation and alleviated neuronal death, especially in aged mice. These findings 
reveal that TRIM9 is essential for resolving NF-κB-dependent neuroinflammation to promote 
recovery and repair after brain injury and may represent an attractive therapeutic target.
Graphical Abstract
In Brief
Neuroinflammation drives pathology during brain injury. Zeng et al. show that TRIM9 is induced 
after ischemic insults in young mice, but not old mice, and promotes resolution of 
neuroinflammation. AAV-mediated TRIM9 therapy in aged mice restricts neuroinflammation and 
alleviates stroke damage, representing a potential therapeutic target for brain injury.
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INTRODUCTION
Tripartite motif containing 9 (TRIM9), a brain-specific ubiquitin (Ub) ligase, is primarily 
expressed in neurons and regulates netrin-dependent axon guidance and morphogenesis 
through the interaction with vasodilator-stimulated phosphoprotein (VASP), a mechanism 
conserved between different species (Hao et al., 2010; Menon et al., 2015; Plooster et al., 
2017; Winkle et al., 2016a, 2016c). We have shown that TRIM9 is a potent inhibitor of 
nuclear factor κB (NF-κB) signaling pathway in in vitro cell culture upon cytokine 
stimulation (Shi et al., 2014). However, the in vivo role of TRIM9 in NF-κB-mediated 
neuroinflammation remains elusive.
Ischemic stroke remains a leading cause of mortality and disabilities in the elderly 
(Benjamin et al., 2017). Excitotoxicity, oxidative and nitrosative stress, necrosis, and 
inflammation are key pathogenic events that contribute to neuronal injury and cell death 
after ischemic stroke (Chamorro et al., 2016; Lo et al., 2005). NF-κB is a master regulator of 
hypoxia-induced inflammation (Eltzschig and Carmeliet, 2011) and plays important roles in 
neuronal plasticity, aging, and degeneration in CNS diseases (Gabuzda and Yankner, 2013; 
Mattson and Camandola, 2001; Salminen et al., 2008; Zhang et al., 2013). NF-κB is a 
dimeric transcription factor consisting members of the Rel family, including Rel-A (p65), c-
Rel, Rel-B, p50, and p52, and is often held in the cytoplasm by inhibitor IkB proteins as its 
latent form (Chen, 2005). Upon stimulation, the IκB kinase (IKK) complex phosphorylates 
the amino-terminal serine residues (S32 and S36) of IκBα, triggering its ubiquitination and 
degradation by the Skp-Cullin-F-box (SCF) Ub ligase complex and the 26S-proteasome 
pathway, respectively (Chen, 2005; Frescas and Pagano, 2008). Consequently, this allows 
the nuclear translocation of NF-κB p50-p65 complex for transcriptional activation of 
targeted genes. NF-κB activation in neurons occurs soon after brain ischemia as evidenced 
by IκBα degradation and p65 phosphorylation (Stephenson et al., 2000), which drives the 
neuronal expression of inflammatory mediators such as inter-leukin 6 (IL-6) (Ohtaki et al., 
2006) and chemokine C-C motif ligand 2 (CCL2) (Stowe et al., 2012). Genetic and 
pharmacological studies targeting NF-κB-activating IKK have shown that inhibiting NF-κB 
is generally beneficial for stroke recovery (Herr-mann et al., 2005; Iadecola and Anrather, 
2011). However, this has been challenged by stroke studies in mouse models with p50 or 
cRel deficiency (Harari and Liao, 2010), as well as in systemic injury models (Elsharkawy 
and Mann, 2007), suggesting that NF-κB-mediated acute inflammatory response is not just 
deleterious. In fact, the acute inflammation responses triggered by CNS injuries usually 
resolve within a short period of time, which set up tissue boundaries for subsequent repair 
process (Buckley et al., 2013; Iadecola and Anrather, 2011; Jin et al., 2010). However, brain-
specific factors that govern inflammation resolution have not been well defined (Iadecola 
and Anrather, 2011). Hence, understanding the brain’s regulatory mechanisms that ensure 
the timely activation and subsequent inactivation of NF-κB-mediated neuroinflammation is 
essential to develop a therapeutic strategy for the recovery and repair after ischemic brain 
injury.
Stroke mostly occurs in elderly people, and outcomes of stroke patients are highly 
influenced by age, indicating that aging is an inherent risk factor for stroke (Markus et al., 
2005; Popa-Wagner et al., 2011). Compared to the young brain, the aged brain displays a 
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compromised ability to resolve stroke-mediated inflammation, causing high susceptibility to 
ischemia and poor functional recovery (Chen et al., 2010). Indeed, upon middle cerebral 
artery occlusion (MCAO), aged mice exhibit elevated proinflammatory mediators, large 
infarction volumes, severe behavioral impairment, and high mortality rates compared to 
young mice (DiNapoli et al., 2008; Jin et al., 2004; Liu et al., 2009; Rosen et al., 2005; 
Shapira et al., 2002), reflecting the effects seen in elderly patients who often experience 
severe functional disabilities following an ischemia (Hankey et al., 2002). However, little is 
known about brain-specific mechanisms that regulate the resolution of neuroinflammation 
that are potentially undermined during aging. Hence, investigating the timely regulation of 
NF-κB-mediated neuroinflammation is key to a better understanding of pathophysiology 
and repair after acute brain ischemia.
Here, we report that TRIM9 provides an innate mechanism to resolve ischemic-stroke-
induced neuroinflammation via fine-tuning of in vivo NF-κB signaling activity in a mouse 
model, and thus, targeting TRIM9 and its related neuroinflammatory pathway may offer a 
target for immunomodulatory therapy for stroke.
RESULTS
TRIM9 Upregulation in the Peri-infarct Brain Region after Ischemic Stroke in Mice
Transient MCAO, which mimics ischemic stroke and reperfusion in rodents, is widely used 
to investigate post-ischemic inflammatory responses and resolution (Liesz et al., 2009; 
Shichita et al., 2009, 2012, 2017). Immunoblotting analysis of NF-κB activation showed that 
IκBα degradation and p65 phosphorylation were evidently induced between 1 and 12 hr 
after 30-min MCAO and returned close to a baseline level after 48 and 72 hr in C57BL/6J 
(wild-type [WT]) mice (Figures 1A and 1B). This was consistent with the self-limiting 
characteristics of post-ischemic inflammation (Liu et al., 2015) that preceded the repair 
processes (Iadecola and Anrather, 2011). We also observed the highly upregulated levels of 
p-p65 in NeuN-positive neurons of the ischemic brains at 12 hr after 30-min MCAO 
compared to those in the sham-operated group (Figures 1C and 1D). When ischemic brain 
tissues isolated 12 hr after surgical procedures were subjected to RNA sequencing (RNA-
seq) analysis, the expression of numerous genes was altered in MCAO-treated tissues 
compared to those in sham-operated tissues (Figure 1E). Remarkably, among those top 20 
upregulated genes, only Trim9 exhibited a brain-specific expression pattern (Berti et al., 
2002) (https://www.ncbi.nlm.nih.gov/gene/94090) (Figure S1A; Table S1). Gene ontology 
analysis showed that Trim9 was in the neurological disease and inflammation pathway in 
which genes experienced the most significant alteration of expressions (adjusted p value < 
0.01) (Figure 1F; Table S2). Immunoblotting assays showed the upregulation of TRIM9 in 
the ischemic brain hemisphere, when compared with the unaffected contralateral hemisphere 
(Figures S1B and S1C). In addition, high resolution in situ hybridization analysis with 
RNAscope gene-specific probes (Wang et al., 2012a) demonstrated that the upregulation of 
Trim9 was primarily detected at the periphery of the ischemic areas in the ipsilateral 
hemisphere, as compared to a basal level of the unaffected contralateral hemisphere (Figure 
1G). In addition, no significant difference of stroke-induced Trim9 expression between 12-
week-old male and female mice was observed (Figure S1D). Taken together, these findings 
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indicate that Trim9 is highly upregulated in the peri-infarct cortical areas of mouse brain 
upon ischemic stroke.
Exacerbated Ischemic Brain Injury in Trim9-Deficiency Mice
Besides aberrant axonal branching in the corpus callosum (Winkle et al., 2014) and 
excessive dendritic arborization of den-tate granule cells in the hippocampus (Winkle et al., 
2016b), Trim9-deficient (Trim9−/−) mice exhibit no gross anatomical defects or impairment 
in motor functions (Winkle et al., 2016b). We found that the numbers of NeuN+ neurons, 
SMI-312+ neuritic density, Oligo2+ oligodendrocytes, NG2+Oligo2+ oligodendrocyte 
precursor cells, GFAP+ astrocytes, and Iba1+ microglia in both the somatosensory cortex and 
hippocampus were nearly identical between Trim9−/− mice and WT Trim9+/+ littermates 
(Figures S2A–S2F). In addition, consistent with the lack of expression in endothelial cells 
(Zhang et al., 2014), Trim9−/− mice showed no change of the middle cerebral artery (MCA) 
territory (Figures S2G and S2H) or alteration of cerebral blood flow (CBF) before, after, and 
during 30-min MCAO (Figures 2A and S2I) compared to WT littermates, indicating that the 
cerebrovascular system was not affected by Trim9 deficiency. By contrast, Trim9−/− mice 
were more prone to ischemic injury than WT litter-mates, exhibiting a 2-fold increase in 
infarct volume (Figures 2B and 2C) and a 2.3-fold enhancement in edema volume (Figure 
2C) at 24 hr after MCAO. Behavioral analysis using a 6-point motor neurological score 
method (Wang et al., 2005) showed an ~2-fold decline of neurological outcomes in Trim9−/− 
mice relative to WT littermates at 24 hr after MCAO (Figure 2C). Cytokines and 
chemokines are important mediators of neuroinflammation in stroke (Chamorro et al., 2012; 
Eltzschig and Carmeliet, 2011; Iadecola and Anrather, 2011). At 24 hr after 30-min MCAO, 
Trim9−/− mice showed a dramatic increase in a panel of inflammatory cytokines, including 
IL-6 and CCL2/5 but no alteration of IL-10 compared to WT littermates (Figures 2D and 
S3A). ELISA showed that tumor necrosis factor α (TNF-α) and IL-1β were marginally 
increased in Trim9−/− mice at 24 hr after 30-min MCAO but became more evident at 36 hr 
(Liesz et al., 2013) (Figure S3B). These data suggest TRIM9 functions in dampening 
neuronal expression of inflammation mediators of IL-6 and CCL2 that are upregulated 
within the first day of stroke (Ohtaki et al., 2006; Stowe et al., 2012). A terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and 
immunohistological analysis also indicated that the ischemic ipsilateral brain regions of 
Trim9−/− mice showed ~2-fold increases in apoptotic cells and neuronal death compared to 
those of WT lit termates (Figures 2E and 2F).
Trim9 Deficiency Causes the Elevation of Peripheral Immune Cell Infiltration in Mouse 
Brain
CCL2 (also known as monocyte chemoattractant protein-1) attracts inflammatory immune 
cells such as monocytes to infiltrate into brain parenchyma under pathological conditions, 
which triggers further neuronal dysfunction and damage (Mennicken et al., 1999). Flow 
cytometry analysis showed that compared to MCAO-treated WT littermates, MCAO-treated 
Trim9−/− mice had significant increases of CD45hiGR1+CD11b+ granulocytes and 
inflammatory monocytes and CD45hiCD11b−CD3e+ T cells (Figures 3). These results 
indicate that TRIM9 plays a critical role in dampening the stroke-induced production and 
recruitment of inflammation mediators and immune cells, respectively.
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TRIM9 Suppresses Neuroinflammation by Inhibiting NF-κB Signaling
To further examine the role of TRIM9 in brain-specific NF-κB activation, ischemic brains 
were harvested 24 hr after MCAO and then subjected to immunoblotting analysis. This 
revealed increased IκBα degradation and p65 phosphorylation (p-p65) in the ischemic 
brains of Trim9−/− mice compared to those of Trim9+/+ mice (Figures S4A and S4B). 
Consistently, immunostaining also showed increases of p-p65-positive neurons (NeuN) in 
the peri-infarct area of Trim9−/− mice (Figures S4C and S4D). To further test this, primary 
cortical neurons isolated from Trim9+/+ and Trim9−/− embryos (Figure S5A) were 
challenged either by 30- or 60-min oxygen-glucose deprivation (OGD) with reoxygenation 
for 24 hr (R24h) or by the pro-inflammatory cytokine TNF-α or IL-1β for 30–120 min. 
Immunoblotting assays showed that the degradation of IκBα was more robust in Trim9−/− 
primary neurons upon stimulation with OGD (Figures 4A and 4B), TNF-α, or IL-1β 
(Figures S5B–S5E) than in Trim9+/+ primary neurons. Correspondingly, the increase of p65 
phosphorylation was also more evident in Trim9−/− primary neurons upon TNF-α or IL-1β 
stimulation than in Trim9+/+ primary neurons (Figures S5B–S5E). Finally, human neural 
progenitor cell (hNPC)-derived neurons (Liang et al., 2016; Wang et al., 2016) were infected 
with scramble- or TRIM9-specific short hairpin RNA (shRNA) lentivirus for 24 hr, followed 
by OGD stimulation for 30- or 60-min shRNA-mediated knockdown of TRIM9 expression 
in hNPC-derived neurons led to robust IκBα degradation and increased p65 phosphorylation 
upon OGD stimulation (Figures S5F and S5G). Furthermore, TRIM9-specific shRNA-
treated hNPC-derived neurons were more vulnerable to OGD-induced cell death than 
scramble shRNA-treated neurons (Figures 4C and 4D). These results indicate that TRIM9 is 
required for neuronal survival under ischemia and inflammation.
As our previous study demonstrates the TRIM9-mediated suppression of NF-κB activation 
via its interaction with β-transducin repeat-containing protein (β-TrCP) (Shi et al., 2014), we 
further showed the TRIM9 and β-TrCP interaction in brain tissue of MCAO-treated or sham-
operated mice (Figure 4E). In addition, primary neurons isolated from Trim9−/− embryos 
were infected with lentivirus containing vector, TRIM9-WT, or S76AS80A (SA) mutant that 
no longer interacts with β-TrCP (Shi et al., 2014), followed by stimulation with OGD, TNF-
α, or IL-1β. Our data showed that the substitution of TRIM9-WT allowed Trim9−/− primary 
neurons to regain their ability to suppress stimulation-induced NF-κB signaling, whereas the 
substitution of the TRIM9-SA mutant showed little or no effect on NF-κB signaling (Figures 
4F, 4G, and S5H–S5K). When lentivirus-infected primary Trim9−/− neurons were treated 
with TNF-α and tested for the β-TrCP interaction with TRIM9 or IκBα, TRIM9-WT, but 
not TRIM9-SA mutant, effectively competed with IκBα for the β-TrCP interaction (Figure 
4H). Consequently, Trim9−/− primary neurons showed a higher IκBα ubiquitination upon 
TNF-α + MG132 treatment than Trim9+/+ primary neurons (Figure 4I). qRT-PCR also 
showed higher expression of the inflammatory mediators IL-6, TNF-α, IL-1β, and CCL2 in 
Trim9−/− primary neurons upon OGD stimulation than in Trim9+/+ primary neurons (Figure 
4J). These results indicate that TRIM9’s interaction with β-TrCP is critical for fine-tuning 
NF-κB signaling and inflamma-tory responses in neurons.
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AAV-PHP.B-Mediated Brain-wide TRIM9 Expression Ameliorates Ischemic Injury in Trim9−/− 
Mice
To explore whether in vivo brain-wide expression of Trim9 could alleviate ischemia-induced 
neuroinflammation and brain injury in mice, we utilized an engineered variant of adeno-
associated virus (AAV) serotype 9 (AAV-PHP.B) that can efficiently transfer genes 
throughout the CNS following systemic delivery (Deverman et al., 2016; Morabito et al., 
2017). AAV-PHP.B-mediated expression of the green fluorescent protein (GFP), the Flag-
tagged murine TRIM9-WT or the SA mutant was readily detected in Trim9−/− mouse 
embryonic fibroblasts (MEFs) and primary neurons (Figure S6A; see also STAR Methods). 
Subsequently, AAV-PHP.B:CAG-GFP (PHP.B-GFP), AAV-PHP.B:CAG-FLAG-TRIM9 
(PHP.B-TRIM9), and AAV-PHP.B:CAG-FLAG-TRIM9-SA (PHP.B-SA) were administrated 
twice to 12-week-old Trim9−/− mice following a retro-orbital injection protocol (Deverman 
et al., 2016) (Figure 5A). GFP and FLAG-tagged TRIM9-WT or SA mutant expression were 
tested 21 days post-injection. Efficient expression of GFP, FLAG-tagged TRIM9-WT, or SA 
mutant was observed in neurons throughout the brain, including the cortex and hippocampus 
(Figures 5B and S6B). When compared with PHP.B-GFP- or PHP.B-SA-infected Trim9−/− 
mice 24 hr after 30-min MCAO, PHP.B-TRIM9-infected Trim9−/− mice showed 
substantially reduced infarct volume (Figures 5C and 5D) and neurological impairments, as 
indicated by neurological scores (Figure 5E). An immunoblotting assay of tissue extracts 
from MCAO-induced ischemic brain hemispheres showed the reduced IκBα degradation in 
PHP.B-TRIM9-infected Trim9−/− mice compared to PHP.B-GFP- or PHP.B-SA-infected 
Trim9−/− mice (Figures S6C and S6D). Finally, when primary neurons isolated from 
Trim9−/− mice were infected with PHP.B-GFP, PHP.B-TRIM9, or PHP.B-SA and then 
subjected to OGD conditions, IκBα degradation was considerably lower in PHP.B-TRIM9-
infected Trim9−/− neurons than in PHP.B-GFP- or PHP.B-SA-infected Trim9−/− neurons 
(Figures S6E and S6F). These results collectively indicate that AAV-PHP.B-mediated brain-
wide TRIM9 expression effectively resolves inflammatory responses in neurons, providing 
neuroprotection against ischemic stroke.
AAV-PHP.B-Mediated Brain-wide TRIM9 Expression Alleviates Ischemic Injury in Middle-
Aged Mice
A previous genome-wide analysis reports that the stroke-induced expression of a specific 
group of genes, including Trim9, is considerably lower in the ipsilateral cortex of aged rats 
than in that of young rats (Buga et al., 2012). A similar level of TRIM9 expression in the 
brain was observed between 12-week-old young mice and 70-week-old middle-aged mice 
under normal conditions. In contrast, the stroke-induced upregulation of TRIM9 expression 
was detectably lower in aged mouse brains than in young mouse brains (Figures 6A and 6B). 
The stroke-induced expression of two key inflammatory mediators, IL-6 (Figures 6C and 
6D) and CCL2 (Figures 6E and 6F), was induced much higher in aged mouse brains than in 
young mouse brains.
To examine in vivo expression of Trim9 to alleviate ischemia-induced neuroinflammation in 
aged mice, 70-week-old C57BL/6J mice were retro-orbitally injected with PHP.B-GFP or 
PHP.B-TRIM9 and subjected to 30-min MCAO, followed by neurological tests at 24 hr. 
When compared with PHP.B-GFP-infected aged mice, PHP.B-TRIM9-infected aged mice 
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showed substantially reduced infarct areas (Figures 6G and 6H) and neurological 
impairments, as indicated by neurological scores (Figure 6I). Confocal microscopy showed 
that compared to PHP.B-GFP-infected aged mice, PHP.B-TRIM9-infected aged mice had 
reduced levels of p-p65-positive neurons (NeuN) in the peri-infarct cortex (Figures 6J and 
6K) and neuronal cell death, as indicated by TUNEL+NeuN+ double-positive cells in the 
infarct cortex (Figures 6L and 6M). The strong correlation between the p-p65-positive 
neuron population level and the motor neurological behavior score was observed in PHP.B-
GFP- or PHP.B-TRIM9-infected aged mice (Figure 6N). These results collectively 
demonstrate that AAV-PHP.B-mediated brain-wide TRIM9 expression effectively alleviates 
neuroinflammation and ameliorates neuropathological and neurological outcomes after 
ischemic stroke.
DISCUSSION
The acute inflammatory response and its resolution are indispensable for body’s 
physiological repair process after injuries, while unresolved inflammation is implicated in a 
body of human diseases, including CNS injuries (Schwartz and Baruch, 2014). 
Inflammation resolution in the CNS is a highly organized active process that requires 
complex crosstalk between injured neurons, glial cells, and infiltrating inflammatory cells 
(Schwartz and Baruch, 2014). However, brain factors that govern the resolution of 
neuroinflammation are yet to be defined (Iadecola and Anrather, 2011). By revisiting the 
brain’s endogenous genes within the inflammatory response network that were activated 
upon ischemic injury, we identified TRIM9 as a brain-specific modulator of NF-κB-
dependent neuroinflammation (Figure 1). It governs the resolution of post-ischemic 
inflammation and consequently improves neuropathological and neurological outcomes in 
the mouse model of acute ischemic stroke (Figure 2). Accordingly, Trim9 deficiency is 
accompanied by elevated pro-inflammatory cytokine production, inflammatory cell 
infiltration, subsequent neuronal death, and exacerbated brain injury after MCAO (Figures 2 
and 3).
Pro-inflammation, anti-inflammation, and pro-resolution signals converge on the NF-κB 
pathway. In acute ischemia, NF-κB activation in injured neurons initiates strong 
inflammatory responses via production of proinflammatory mediators. TRIM9 expression is 
strongly increased in the peri-infarct area in a mouse stroke model (Figure 1G). This delayed 
surge of Trim9 expression ensures timely antagonization of NF-κB activity and tissue 
resolution of inflammation, as we showed that the brain-wide expression of TRIM9 
effectively promoted resolution of neuroinflammation and alleviated neuronal death in 
TRIM9-deficient mice (Figure 5). Our findings indicated that the balance between these 
pathways could be adjusted temporally by TRIM9 after ischemic stroke. AAV-PHP.B-
mediated TRIM9 expression ameliorates the ischemic neuropathology and neurological 
outcomes in young Trim9−/− mice (Figure 5) and 70-week-old WT mice (Figure 6). This 
suggests that targeting TRIM9 for better resolution of neuroinflammation may offer a 
potential target for immunomodulatory therapy for acute ischemia. Previous studies have 
shown that the infiltration pattern of peripheral immune cells and timing of immune 
activation differ in stroke (Chamorro et al., 2012; Iadecola and Anrather, 2011; Jin et al., 
2010), suggesting that the infarct or behavior could possibly change over time. Investigation 
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of stroke-related neuropathology on later time-point than 24 hr could provide more useful 
information about the resolution of inflammation, especially in aged mice.
Older women have a much higher incidence of stroke than men as well as a worse prognosis, 
which is recapitulated in rodent model; for instance, aged female mice display a larger 
infarct volume upon stroke than aged male mice (Liu et al., 2009). In the current study, aged 
female mice were specifically chosen to evaluate the therapeutic potential of AAV-based 
gene therapy, since TRIM9 expression was similar between young male and female mice 
(Figure S1D). As a huge body of literature on stroke and inflammation has used young male 
mice as MACO animal models (Herrmann et al., 2005; Kawano et al., 2006; Liesz et al., 
2009, 2013; Reischl et al., 2014; Sarabi et al., 2008; Shichita et al., 2009, 2012, 2017; 
Strecker et al., 2011; Wang et al., 2016), and we also utilized young male mice to maintain 
consistency with previous studies. It is well known that the aged population is not only 
highly susceptible to ischemic stroke but also shows slow recovery from ischemic stroke. 
However, the basis of this high susceptibility and slow recovery of the aged population is 
very complex, with numerous contributing factors. We found that the upregulation of 
TRIM9 expression appeared to be critical to resolve inflammation in the peri-infarct region 
of brain and minimize the injury size. However, this stroke-induced upregulation of TRIM9 
expression was compromised in aged mice, causing sustained neuroinflammation and 
enhanced ischemic damage. Induction of Trim9 expression in the peri-infarct areas of 
ischemic brain occurred during the early stage. Additional studies are necessary to 
understand the molecular mechanism of Trim9 expression under normal conditions versus 
ischemic stroke conditions.
The MCAO model we used here is an acute stroke mouse model, which does not allow a 
sufficient time window for target gene delivery for gene therapy. For example, while AAV 
mutant AAV-PHP.B enabled brain-wide expression of TRIM9 gene with high efficiency 
(Deverman et al., 2016), TRIM9 gene delivery still required days (or even more than a 
week) after AAV injection. Alternative methods to quickly upregulate endogenous TRIM9 
expression may provide its systemic expression for post-stroke treatment. Lastly, the pre-
stroke strategies may be utilized as prevention approaches, which would represent a 
potential therapeutic method for the aging population, especially in at-risk older women. 
Further study is needed to evaluate a number of methods to upregulate brain-specific TRIM9 
expression.
Parkinson’s disease (PD), the second most common age-associated neurodegenerative 
disorder, is characterized by the loss of dopaminergic neurons (Obeso et al., 2010), as well 
as chronic neuroinflammation (McGeer and McGeer, 2004). Specifically, post-mortem 
analyses of human PD patients and experimental animal studies shows that the chronic 
increase of proinflammatory cytokines and the infiltration and accumulation of immune cells 
from the periphery are also implicated in the pathogenesis of PD (Barcia et al., 2003; Hirsch 
and Hunot, 2009; Hirsch et al., 2012). Intriguingly, a previous study showed that Trim9 
expression was significantly downregulated in the brains of PD and Lewy body dementia 
(Tanji et al., 2010). We showed that AAV-PHP.B-mediated Trim9 expression markedly 
reduced neuroinflammation in young Trim9−/− mice (Figure 5) and middle-aged WT mice 
(Figure 6), leading to improvement of the ischemic neuropathology and neurological 
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outcomes. This suggests that manipulating Trim9 expression for better resolution of 
neuroinflammation may offer prospect to immunomodulatory therapy for PD, ischemic 
stroke, and even other neurodegenerative diseases. A better understanding of the role of 
TRIM9-mediated regulation of inflammation would provide insight into the 
neuropathological processes and help to establish effective therapeutic strategies.
STAR★METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and request for resources and reagents should be directed to and will be 
fulfilled by Lead Contact Jae U. Jung (jaeujung@med.usc.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture—HEK293 cells were purchased from ATCC (catalog # CRL-11268; the sex is 
female) and maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 
100 U ml−1 penicillin-streptomycin. IL-1β (Biolegend, catalog # 575102), TNF-α 
(Biolegend, catalog # 575202), and proteasome inhibitor MG132 (R&D Systems, catalog # 
1748) were used for stimulation on mouse primary neurons.
Mouse primary neuron culture—Cerebral cortices from E18 mouse embryos (the sex is 
unavailable) were dissected, carefully stripped of their meninges, digested with TrypLE 
Express Enzyme (Thermo Fisher Scientific, catalog # 12604013) with DNaseI (0.5 mg/ml) 
(Sigma, catalog # AMPD1) for 20 min at 37°C, and dispersed to single-cell level by passing 
through a cell strainer (70 μm). The cell suspension was then cultured with Neurobasal 
medium supplemented with B27 Supplement (Thermo Fisher Scientific, catalog # 
17504044) at 37°C in humiliated 5% CO2, 95% air on poly-D-Lysine (Millipore, catalog # 
A-003-E) and laminin (Thermo Fisher Scientific, catalog # 23017015) pre-coated coverslips 
or in 12-well culture plates. Medium was replaced at 50% every other day.
Human neural progenitor cell (hNPC)-derived neurons—Human neural progenitor 
cell (hNPC) from fetal origin (the sex is unavailable) (Guo et al., 2013; Wang et al., 2010) 
were maintained as neurospheres in DMEM/F12-N2 supplemented with 20 ng/ml (1.4 nM) 
bFGF (Sigma-Aldrich, St. Louis, MO) in low-attachment T-25 flasks (Corning, Acton, MA) 
(Wang et al., 2016). For differentiation, hNPC were plated on poly-L-Orthithine (10 μg/ml) 
and laminin (10 μg/ml) coated round cover glasses in 4-well plates at a density of 4 × 105 
per well in STEMdiff Neuron Maturation medium (StemCell Technologies, Inc.) and 
incubated for 10 days in vitro to allow for differentiation.
Mouse embryo fibroblasts (MEFs)—MEFs from Trim9−/− mice (the sex is unavailable) 
was isolated and cultured, as previously described (Durkin et al., 2013). Briefly, E13 
embryos were harvested and digested by 0.25% trypin-EDTA. Cell suspension was cultured 
with MEF culture medium containing DMEM supplemented with 10% FBS and 100 U ml−1 
penicillin-streptomycin in T75 flasks.
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Mice—The Institutional Animal Care and Use Committee at the University of Southern 
California approved all procedures per the National Institutes of Health guidelines. Mice 
were housed in plastic cages on a 12h light cycle, with ad libitum access to water, with 
standard laboratory diet, and in a specific pathogen-free facility. Trim9+/− heterozygous mice 
(Winkle et al., 2014) were bred to generate age-matched Trim9−/− and littermates Trim9+/+ 
mice. Male (Liesz et al., 2009; O’Collins et al., 2006; Shichita et al., 2009, 2012) Trim9+/+ 
and Trim9−/− mice with 12-week-old were used. C57BL/6J mice were purchased from the 
Jackson Laboratory (JAX stock 000664). Because there is a significant sex effect on the 
pathology of brain ischemia (Liu et al., 2009; Wendeln et al., 2018), where both male and 
female mice were compared, only female aged C57BL/6J mice with 70-week-old were used 
in the present study. All the animals that survived surgical procedures were included in the 
study. All animals were randomized for all stroke studies and procedures. All experiments 
were blinded; the operators responsible for experimental procedure and data analysis were 
blinded and unaware of group allocation throughout the experiments.
METHOD DETAILS
Transient middle cerebral artery occlusion (MCAO)—Using a 27-½ gauge needle, 
mice were anesthetized with 100 mg/kg Ketamine intraperitoneally (IP) and 10 mg/kg IP 
xylazine. Rectal temperature was maintained at 37°C using a feedback-controlled heating 
system. MCA was occluded for 30 minutes using a silicon-coated nylon monofilament 
(DOCCOL, CO) as we previously described (Wang et al., 2012b). Cerebral blood flow was 
monitored by laser Doppler flowmetry (Transonic Systems). Mice with an adequacy of 
MCAO as evidenced by R 80% drop in the cerebral blood flow were included in the study. 
Motor neurological examination was determined after 24 hours, using the following criteria: 
no neurological deficit, 0; failure to extend left forepaw fully, 1; turning to left, 2; circling to 
left, 3; unable to walk spontaneously, 4; and stroke-related death, 5. All mice were 
euthanized 0, 1, 4, 12, 24, 36, 48, or 72 hours after the MCAO for indicated analysis. All 
animals that were survived from surgical procedures were included in the study.
Immunoblotting—Brain tissue or cell lysates were collected in 1% NP40 buffer with the 
protease inhibitor cocktail (Roche, catalog # 4693159001) and phosphatase inhibitor 
PhosSTOP (Roche, catalog # 4906845001), and protein amounts were quantified by BCA 
protein assay kit (Thermo Fisher Scientific, catalog # 23227). Proteins were separated by 
SDS-PAGE and transferred to PVDF membrane (Bio-Rad, catalog # 1620177)) by semi-dry 
transfer at 25V for 30 min. All membranes were blocked in 5% milk in PBST for 1 h and 
probed overnight with indicated primary antibodies in 5% BSA at 4°C. Primary antibodies 
included: mouse monoclonal anti-IκBα antibody (Cell Signaling, catalog # 9247, 1:2000), 
rabbit monoclonal anti-phospho-IκBα antibody (Cell Signaling, catalog # 2859, 1:1000), 
rabbit monoclonal anti-phospho-p65 antibody (Cell Signaling, catalog # 3033, 1:1000), 
mouse monoclonal anti-β-actin antibody (Santa Cruz, catalog # sc-47778, 1:2000), rabbit 
polyclonal anti-TRIM9 antibody (Winkle et al., 2014) (1:2000, generated using murine 
TRIM9 recombinant protein aa 158–271; reacting with three isoform a/b/c), mouse 
monoclonal anti-ubiquitin antibody (Santa Cruz, catalog # sc-8017, 1:1000), rabbit 
monoclonal anti-β-TrCP antibody (Cell Signaling, catalog # 4394, 1:1000), mouse 
monoclonal anti-HA antibody (Santa Cruz, catalog # sc-57594, 1:2000), mouse monoclonal 
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anti-GFP antibody (Santa Cruz, catalog # sc-101525, 1:2000), and mouse monoclonal anti-
Flag antibody (Sigma, catalog # F1804, 1:2000). Appropriate HRP-conjugated secondary 
antibodies were incubated on membranes in 5% milk and bands were developed with 
ChemiDoc Touch imaging system (Bio-Rad) and analyzed in Image Lab software.
Tissue staining—At endpoint, mice were anesthetized and transcardially perfused with 
PBS and fixed with 4% PFA. Mouse brains were post-fixed overnight in 4% PFA at 4°C. For 
cryosectioning, fixed tissues were cryoprotected in 30% sucrose in PBS overnight at 4°C 
and embedded in Tissue-Tek OCT compound (VWR, catalog # 25608–930). Cryostat 
sections were cut at 20 μm thickness. Mouse brain sections were permeabilized in PBS-T 
(PBS containing 0.2% Triton X-100) for 10 min, blocked with 5% normal donkey serum 
(Jackson ImmunoResearch, catalog # 017-000-121) for 60 min and incubated in primary 
antibody diluted in the blocking solution overnight at 4°C. Primary antibodies used in this 
study include mouse monoclonal anti–glial fibrillary acidic protein (GFAP) (cell signaling, 
catalog # 3670), Rabbit monoclonal anti-Iba1 (Abcam, catalog # ab178846), Rabbit 
polyclonal anti-NeuN (Millipore, catalog # ABN78), Mouse monoclonal anti-NeuN 
(Millipore, catalog # MAB377), Mouse monoclonal anti-SMI-312 (Abcam, catalog # 
ab24574), Rabbit polyclonal anti-NG2 (Abcam, catalog # ab83178), Mouse monoclonal 
anti-Olig2 (Abcam, catalog # MABN50), Mouse monoclonal anti-Flag (Sigma, catalog # 
F1804), Rabbit monoclonal anti-phospho-p65 (Cell Signaling, catalog # 3033), Rat 
monoclonal anti-IL6 (Thermo Fisher Scientific, catalog # AMC0864), and Rabbit polyclonal 
anti-CCL2 (Abcam, catalog # 9779). After three washes with PBS, sections were incubated 
with the secondary antibodies for 1 h, including Alexa 488-conjugated donkey anti-mouse 
(Thermo Fisher Scientific, catalog # A21202), Alexa 488-conjugated donkey anti-rabbit 
(Thermo Fisher Scientific, catalog # A-21206), Alexa 568-conjugated donkey anti-mouse 
(Thermo Fisher Scientific, catalog # A10037), Alexa 568-conjugated donkey anti-rabbit 
(Thermo Fisher Scientific, catalog # A10042), Alexa 647-conjugated donkey anti-rabbit 
(Thermo Fisher Scientific, catalog # A-31573), Alexa 488-conjugated donkey anti-rat 
(Thermo Fisher Scientific, catalog # A-21208), and Alexa 647-conjugated donkey anti-rat 
(Jackson ImmunoResearch Laboratories, catalog # 712-605-153). All images were taken 
with the Zeiss 510 confocal microscopy or using the BZ 9000 all-in-one Fluorescence 
Microscope from Keyence (Osaka, Japan), and analyzed using NIH ImageJ software.
RNA sequencing—RNA was prepared using TRIzol Reagent (Thermo Fisher Scientific, 
catalog # 15596018) followed by RNeasy Mini Kit (QIAGEN, catalog # 74104). The 
libraries were made using KAPA stranded mRNA-seq kits (KAPA Biosystems, catalog # 
kk8421) according to manufacturer’s protocol. The cDNA libraries were sent to the 
Technology Center for Genomics & Bioinformatics at UCLA for sequencing on HiSeq 3000 
with single end read (~30 million reads per sample). RNA-seq data was inspected by FastQC 
(Simon, 2010). Using default settings, STAR version 2.5.2b (Dobin et al., 2013) were used 
to map reads to mouse genome GRCm38. Alignment results were processed for gene 
quantification using featureCounts version 1.5.1 (Liao et al., 2014) with the second strand-
specific option. Differentially expressed genes were determined using DESeq2 version 
1.14.1 (Love et al., 2014). The significantly changed genes were analyzed using the 
Ingenuity Pathway Analysis tool for functional analysis. The comparison of expression 
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levels of the upregulated genes was performed by RPKM value of each gene from existing 
RNaseq data in NCBI.
RNAscope in situ hybridization—Trim9 mRNA transcripts were detected using murine 
gene-specific probe (Advanced Cell Diagnotics, catalog # 479071) and visualized using the 
RNAscope 2.5 HD Reagent Kit RED (Advanced Cell Diagnotics, catalog # 322360) on 4% 
paraformaldehyde (PFA) fixed frozen mouse brain tissue sections, according the 
manufacturer’s instructions, followed by counterstaining with hematoxylin (Vector 
Laboratories, catalog # H3401). Sections were imaged using the BZ 9000 all-in-one 
Fluorescence Microscope from Keyence (Osaka, Japan), and analyzed using NIH ImageJ 
software.
Visualization of the anastomotic line between the middle cerebral artery 
(MCA) and anterior cerebral artery (ACA)—We performed an assay with the 
procedures as previously described (Wang et al., 2005). Briefly, latex mixed with carbon 
black was injected through the cannulated aorta of mouse. Anastomotic lines between the 
MCA and the ACA territories were determined by tracing peripheral branches on dorsal 
brain surfaces of mice to the points at which vessels were connected (dotted red line).
Cresyl violet staining and neuropathological analysis—Mouse brain sections from 
five equidistant rostrocaudal brain levels, at −1.6 mm, 0.8 mm, 0 mm, 0.8 mm and 1.6 mm 
from bregma, were fixed by methanol and stained with the Cresyl Echt Violet staining − kit 
(American − MasterTech, catalog # AHC0443). Sections were digitized and transformed 
into gray model, and the border between infarct and non-infarct tissue was outlined using an 
image analysis system (ImageJ). On these sections, infarct volume and brain swelling were 
quantified. The infarct volume was calculated by subtracting the volume of the non-lesioned 
area in the ipsilateral hemisphere from the volume of the whole area in the contralateral 
hemisphere (Wang et al., 2013). The edema volume was calculated by subtracting the 
volume of the contralateral hemisphere from the volume of the ipsilateral hemisphere (Wang 
et al., 2005).
RT-qPCR—Total RNAs were extracted from mouse brain tissues or mouse primary neurons 
using TRIzol Reagent (Thermo Fisher Scientific, catalog # 15596018) followed by RNeasy 
Mini Kit (QIAGEN, catalog # 74104) according to the manufacturer’s instructions. The 
purified RNA was reversely transcripted to cDNA using iScript cDNA Synthesis Kit (Bio-
Rad, catalog # 1708891). All gene transcripts were quantified by quantitative PCR using iQ 
SYBR Green supermix (Bio-Rad, catalog # 1708880) on CFX96 real-time PCR system 
(Bio-Rad). Primer sequences are listed in Table S3.
ELISA—Mouse brain tissues were isolated and homogenized mechanically. The resulting 
supernatants were collected and their concentration of IL-6, IL-1β, TNF-α or IL-10 was 
determined with a mouse-specific ELISA kit (BD Biosciences, catalog # 555240 for IL-6, 
559603 for IL-1β, 555268 for TNF-α, 555252 for IL-10), and this was followed by analysis 
with the FilterMax F5 multi-mode microplate reader (Molecular Devices).
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TUNEL staining—Terminal deoxynucleotidyl transferase-mediated dUTP nick 
endlabeling (TUNEL) assay was employed to demonstrate apoptotic cells. Using the In Situ 
Cell Death Detection Kit, Fluorescein (Roche, catalog # 11684795910) or In Situ Cell Death 
Detection Kit, TMR red (Roche, catalog # 12156792910), brain sections were treated 
following the procedure specified by the manufacturer.
Analyzing infiltrating immune cells—The mice were transcardially perfused with PBS 
containing 0.05 M EDTA extensively to remove blood cells in the circulation. The forebrain 
(bregma from −3 to 3) of the hemisphere was removed and dissociated using neural tissue 
dissociation kit (MACS Miltenyl Biotec, catalog # 130093231). Ipsilateral (ischemic) 
hemisphere of the forebrain was used while contralateral hemisphere of the fore-brain was 
used as sham control. Debris was removed by Debris Removal Solution (MACS Miltenyl 
Biotec, catalog # 130109398) followed by removal of red blood cells (Biolegend, catalog # 
420301). Cell suspensions were stained with propidium iodide (Invitrogen, catalog # P3566) 
and fluorochrome-conjugated antibodies including CD45 (APC/Cy7, 1:100, catalog # 
103116), CD11b (eFluor450, 1:100, catalog # 48-0112-82), CD11c (PE/Cy7, 1:100, catalog 
# 117318), CD3e (PerCP/Cy5.5, 1:100, catalog # 100328), or GR1 (APC, 1:100, catalog # 
108412). Subsequently, the stained suspensions were analyzed with BD FACSCanto II flow 
cytometer and analyzed with FlowJo software. Each cell type was indicated by percentage of 
CD45 positive cells. All antibodies were purchased from eBioscience or BD PharMingen. 
Propidium iodide staining was used to gate live cells.
Immunocytochemistry—Cultured mouse primary neurons were fixed with 4% PFA at 
room temperature for 20 min, permeabilized, and stained with primary antibodies, including 
rabbit polyclonal anti-TRIM9(Winkle et al., 2014) and mouse monoclonal anti-MAP2 
(Abcam, catalog # ab11267), followed by incubation of secondary antibodies including 
Alexa 488-conjugated donkey anti-mouse (Thermo Fisher Scientific, catalog # A21202) and 
Alexa 568-conjugated donkey anti-rabbit (Thermo Fisher Scientific, catalog # A10042). All 
images were taken with the BZ 9000 all-in-one Fluorescence Microscope from Keyence 
(Osaka, Japan) and analyzed using NIH ImageJ software.
Oxygen and Glucose Deprivation (OGD)—Mouse primary cortical neurons or hNPC-
derived neurons were treated with OGD by replacing culture medium with a glucose-free 
Neurobasal medium (Thermo Fisher Scientific, catalog # 21103049), and they were 
immediately placed in a hypoxic incubator chamber (STEMCELL, catalog # 27310) flushed 
with a gas mixture of 94%N2/5%CO2/1%O2. After OGD for the indicated time, medium 
was replaced by standard medium, and cells were cultured under normal condition for 
reoxygenation of 24 h.
Lentivirus infection—Lentiviral vector-mediated in vitro gene delivery was performed as 
previously described (Shi et al., 2014). Briefly, hNPC-derived neurons or mouse primary 
neurons were cultured with medium containing 5 μg/ml polybrene (Sigma, catalog # H9268) 
and 5 × 105 infectious units of lentiviruses containing the following: scrambled shRNA, 
TRIM9-specific shRNAs (target sequence for human: 5-
CGATGCCCTCAACAGAAGAAA-3), pCDH lentivirus expressing mouse HA-TRIM9, or 
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pCDH lentivirus expressing HA-SA mutant of TRIM9. At 48 h post infection, cells were 
further treated with OGD or other conditions as indicated.
Live-Dead Cell assay—hNPC-derived neurons were washed with PBS. LIVE-DEAD 
Viability/Cytotoxicity Kit (Thermo Fisher Scientific, catalog # L3224) was used to quickly 
discriminate live from dead cells by simultaneously staining with green-fluorescent calcein-
AM to indicate intracellular esterase activity and red-fluorescent ethidium homodimer-1 to 
indicate loss of plasma membrane integrity. The samples were immediately imaged by the 
BZ 9000 all-in-one Fluorescence Microscope from Keyence (Osaka, Japan) and analyzed 
using ImageJ software.
Immunoprecipitation—For co-IPs, brain tissues and cells were lysed with RIPA 
minimum lysis buffer (Millipore, catalog # 20–188)). After clarification and pre-clearing, 
protein amounts were quantified by BCA protein assay kit (Thermo Fisher Scientific, 
catalog # 23227). 1/10 of cell lysates were heated as whole cell lysate in immunoblotting, 
and the remained 9/10 lysates were incubated for 16 h with indicated antibodies, followed 
by additional incubation with Pierce Protein A/G Agarose (Thermo Fisher Scientific, catalog 
# 20422) for 2h. Immune complexes were washed with lysis buffer and subjected to 
immunoblotting analysis. For ubiquitination, cells were initially lysed with RIPA buffer 
containing 1% SDS, then cell extracts were diluted with RIPA buffer to 0.1% SDS 
concentration. Finally 1/9 of the diluted extracts were heated as whole cell lysate in 
immunoblotting and the remained 9/10 lysates were subjected to IP and IB.
Adenovirus associated virus (AAV) mediated in vivo delivery of Trim9—For in 
vivo delivery of Tirm9 to the central nervous system, we intravenously injected 12-week-old 
Trim9−/− mice or 70-week-old C57BL/6J mice at retro-orbital site using a AAV-PHP.B 
vector, a method that allows widespread gene transfer to the adult brain (Deverman et al., 
2016), either expressing mouse Trim9 (NM_001110203.1) under the control of a CAG 
promoter (AAVPHP.B:CAG-TRIM9), TRIM9-SA mutant (AAV-PHP.B:CAG-TRIM9-SA), 
or a control vector encoding the green fluorescent protein (AAV-PHP.B:CAG-GFP). Retro-
orbital injections of 1.5 × 1012 genome copies per mouse was performed twice at 21 and 18 
days before MCAO, to allow sufficient re-expression of TRIM9 in the CNS.
QUANTIFICATION AND STATISTICAL ANALYSIS
The sample size chosen for our animal experiments in this study was estimated based on our 
prior experience performing similar experiments. For all the bar graphs, data was expressed 
as mean ± s.d. The various types of statistical analysis were performed using GraphPad 
Prism and by an investigator blinded to the experimental conditions, including two-way 
ANOVA test, Mann-Whitney U test, Wilcoxon matched pair test, one-way ANOVA followed 
by Tukey’s post hoc analysis, one-way ANOVA followed by Bonferroni’s post hoc analysis, 
and two-tailed Student’s t test was performed using GraphPad Prism. P value < 0.05 was 
considered statistically significant.
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Highlights
• TRIM9 expression is increased in the peri-infarct area shortly after ischemic 
stroke
• Trim9-deficiency mice are more vulnerable to ischemia than wild-type mice
• AAV-mediated brain-wide TRIM9 expression ameliorates ischemic injury in 
mice
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Figure 1. Upregulation of TRIM9 Expression in the Brains of MCAO Mice
(A and B) Representative immunoblots (A) and quantification (B) of IκBα degradation and 
NF-κB subunit p65 phosphorylation (p-p65) in tissue extracts of the ischemic brain 
hemispheres of 12-week-old C57BL/6J mice upon 30-min MCAO followed by various time 
points of reperfusion (R). Whole-tissue lysates were used for immunoblotting with 
antibodies against IκBα, p-p65, and actin. n = 3 mice per group.
(C and D) Representative confocal images (C) and quantifications (D) of p-p65 positive 
neurons (NeuN) in the infarct cortex of C57BL/6J mice 12 hr after 30-min MCAO. Scale 
bar, 20 μm. n = 3 mice per group. **p < 0.01 by Student’s t test.
(E) Analysis of differential gene expression was based on RNA-seq and is presented as a 
volcano plot in the mouse ischemic hemispheres 12 hr after 30-min MCAO. Genes with over 
2-fold expression changes are labeled blue and red. In this plot, the −log10 p value of each 
gene is plotted (on the vertical axis) against its log2 fold change (on the horizontal axis). 
Some of the top 20 upregulated genes based on adjusted p value are labeled in the black box 
on the right side. n = 2 mice in the sham group, and n = 3 mice in the MCAO group.
(F) Gene ontology enrichment analysis of the genes (plot based on −log10 p values for each 
pathway) in (E).
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(G) In situ detection of Trim9 mRNA using RNAscope probes on brain sections (at 0 mm 
from the bregma) of wild-type Trim9+/+ mice 12 hr after 30-min MCAO or sham-operated 
littermates. Sham-operated Trim9−/− mice were included as controls. The closed dotted line 
indicates the infarct area. Scale bar, 50 mm. n = 3 mice per group.
Data in (B) and (C) are shown as mean ± SD.
See also Figure S1.
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Figure 2. Trim9 Deficiency Exacerbates Ischemic Brain Injury in Mice
(A) A diagram of the experimental procedures of ischemic stroke in mice.
(B) Representative cresyl violet staining images of the brain sections (at +1.6, +0.8, 0, −0.8, 
or −1.6 mm from the bregma) from Trim9+/+ and Trim9−/− mice 24 hr after 30-min MCAO. 
The closed lines indicate infarct areas. n = 8 mice per group.
(C) Dot plots and quantifications of infarct volume, edema volume, and motor neurological 
scores of individual mouse from B. **p < 0.01 and ***p < 0.001 by Mann-Whitney U test.
(D) qRT-PCR analysis of a panel of inflammatory mediators in ischemic brain tissues of 
Trim9+/+ and Trim9−/− mice 24 hr after 30-min MCAO. n = 5 mice per group. ***p < 0.001 
by one-way ANOVA and Bonferroni’s post hoc test. ns, non-significant.
(E and F) Representative confocal images (E) and quantification (F) of neuronal death based 
on a neural marker NeuN and TUNEL assay in the ischemic ipsilateral brain regions of 
Tirm9+/+ and Trim9−/− mice 24 hr after 30-min MCAO. TUNEL+ and NeuN+ and TUNEL+ 
indicate total number of cell death and neuronal cell death (%), respectively. Scale bar, 30 
μm. n = 5 mice per group. ***p < 0.001 by Student’s t test.
Data in (C), (D), and (F) are shown as mean ± SD.
See also Figures S2 and S3.
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Figure 3. Trim9 Deficiency Causes the In crease of Peripheral Immune Cell Infiltration in the 
Brain after Stroke
(A) Flow cytometry analysis of immune cells infiltrating into the ischemic hemisphere of 
Trim9+/+ and Trim9−/− mice 24 hr after 30-min MCAO. The R1 population of CD45+ cells 
was selected and further gated for GR1+CD11b+ granulocytes or inflammatory monocytes 
(R2) and CD11b− lymphocytes (R3). The R3 population was further gated for CD3e+ T 
cells.
(B) Infiltrating immune cells. GR1+CD11b+ granulocytes or inflammatory monocytes and 
CD3e+ T cells were presented as the percentage of CD45+ cells. n = 4 mice per group. *p < 
0.05 and ***p <0.001 by one-way ANOVA and Bonferroni’s post hoc test. Data are shown 
as mean ± SD.
Zeng et al. Page 25
Cell Rep. Author manuscript; available in PMC 2019 April 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. TRIM9 Suppresses NF-κB Signaling by Competing with IκBα for β-TrCP Interaction
(A and B) Representative immunoblots (A) and quantification (B) of IκBα in primary 
cortical neurons isolated from Trim9+/+ and Trim9−/− embryos stimulated by 30 or 60 min of 
oxygen-glucose deprivation (OGD) followed by reoxygenation (R24h). Whole-cell lysates 
(WCLs) were used for immunoblotting with anti-TRIM9 and anti-actin antibody. **p < 0.01 
by Student’s t test.
(C and D) Representative images (C) and quantification (D) of Live-Dead viability assays 24 
hr after 30-min OGD stimulation of human neural progenitor cell (hNPC)-derived neurons 
transduced with scramble or TRIM9-specific shRNA lentivirus. Scale bar, 30 μm.
(E) Representative immunoblots of the β-TrCP-TRIM9 interaction. Ischemic brain tissues of 
Trim9+/+ and Trim9−/− mice 24 hr after 30-min MCAO were used for immunoprecipitation 
(IP) with anti-β-TrCP, followed by immunoblotting (IB) with anti-β-TrCP or anti-TRIM9. 
WCLs were also used for IB with various antibodies. Ct Ig, isotype control immunoglobulin.
(F and G) Representative immunoblot (F) and quantification (G) of IκBα in Trim9−/− 
primary neurons transduced with lentivirus carrying vector (Vec), mouse hemagglutinin 
(HA)-TRIM9 wild-type (WT), or HA-TRIM9 SA mutant 24 hr after 30- or 60-min OGD. 
**p < 0.01 by Student’s t test. ns, non-significant.
(H and I) Comparison between the β-TrCP-TRIM9 interaction and the β-TrCP-IκBα 
interaction (H) and IκBα ubiquitination (I). Trim9−/− primary neurons transduced with Vec, 
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TRIM9 WT, or TRIM9 SA mutant lentivirus were stimulated with mock (−) or TNF-α (25 
ng/ml) + MG312 (10 μM) (+) for 1 hr (see STAR Methods for details). WCLs were used for 
IP with anti-β-TrCP, followed by IB with anti-IκBα or anti-HA (H) or for IP with anti-
IκBα, followed by IB with anti-ubiquitin antibody (I). WCLs were also used for IB with 
antibodies against IκBα, p-IκBα, HA, β-TrCP, TRIM9, or actin.
(J) qRT-PCR analysis of a panel of inflammatory mediators, including IL-6 and CCL2, in 
Trim9+/+ (blue) and Trim9−/− (red) primary neurons primary neurons 24 hr after 30-min 
OGD treatment. **p < 0.01 and *p < 0.05 by one-way ANOVA and Bonferroni’s post hoc 
test.
Data in (B), (D), (G), and (J) are from three independent experiments, shown as mean ± SD.
See also Figures S4 and S5.
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Figure 5. Noninvasive AAV-PHP.B-Mediated Brain-wide TRIM9 Expression Alleviates Ischemic 
Injury in Trim9−/− Mice
(A) A diagram of the experimental design. Trim9−/− mice were retro-orbital injected twice 
with 1.5 × 1012 genome copy of recombinant AAV vector, including AAV-PHP.B:CAG-GFP 
(PHP.B-GFP), AAV-PHP.B:CAG-FLAG-TRIM9 (PHP.B-TRIM9), and AAV-PHP.B:CAG-
FLAG-TRIM9-SA (PHP.BSA). These mice were tested 21 days or 18 days prior to MCAO 
conditions.
(B) Representative images of GFP and FLAG-TRIM9 expression in brain sections 21 days 
post-infection of recombinant AAV. Scale bar, 50 μm. n = 3 mice per group.
(C) Representative cresyl violet staining images of the brain sections (at +1.6, +0.8, 0, −0.8, 
or −1.6 mm from the bregma) of recombinant AAV-infected Trim9−/− mice that were tested 
24 hr after 30-min MCAO. The area within the closed line indicates injured tissue. Scale bar, 
30 μm. n = 8 mice per group.
(D and E) Quantification of infarct volume (D) and motor neurological scores (E) of 
individual mice described in (C). **p < 0.01 by one-way ANOVA and Tukey’s post hoc test. 
ns, non-significant. Data are shown as mean ± SD.
See also Figure S6.
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Figure 6. AAV-PHP.B-Mediated Brain-wide TRIM9 Expression Ameliorates Ischemic Injury in 
C57BL/6J Middle-Aged Mice
(A and B) Representative immunoblots (A) and quantification (B) of TRIM9 in brain tissue 
extracts of the ischemic brain hemispheres of C57BL/6J young or aged mice upon 30-min 
MCAO, followed by 12-hr reperfusion. Whole-tissue lysates were used for immunoblotting 
with antibodies against TRIM9 and actin. Isoform b was used for quantification. n = 4 mice 
per group. *p < 0.05 by one-way ANOVA and Bonferroni’s post hoc test. ns, non-
significant.
(C–F) Representative confocal images and quantifications of IL-6-positive (C and D) and 
CCL2-positive (E and F) neurons (NeuN) in the ischemic ipsilateral cortex regions of 12-
week-old (12W) and 70-week-old (70W) C57BL/6J mice 12 hr after 30-min MCAO. Scale 
bar, 30 μm. n = 4 mice per group. **p < 0.01 by Student’s t test.
(G) Representative cresyl violet staining images of the brain sections (at +1.6, +0.8, 0, −0.8, 
or −1.6 mm from the bregma) of recombinant AAV-infected aging mice that were tested 24 
hr after 30-min MCAO. The area within the closed line indicates injured tissue. Scale bar, 30 
μm. n = 8 mice per group.
(H and I) Quantification of infarct volume (H) and motor neurological scores (I) of 
individual mice described in (G). The dashed line indicates the mean value from Trim9+/+ 
mice in Figure 2c. *p < 0.05 and **p < 0.01 by Mann-Whitney U test. ns, non-significant.
(J and K) Representative confocal images (J) and quantification (K) of p-p65-positive 
neuronal cells in the peri-infarct regions of ischemic brain of recombinant AAV-infected 
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aging mice 24 hr after 30-min MCAO. Scale bar, 30 μm. n = 8 mice per group. **p < 0.01 
by Mann-Whitney U test.
(L and M) Representative confocal images (L) and quantifications (M) of neuronal death 
based on a TUNEL assay in the infarct region of ischemic brain of aging mice injected with 
the indicated AAV 24 hr after 30-min MCAO. Scale bar, 30 mm. n = 5 mice per group. **p 
< 0.01 by Mann-Whitney U test.
(N) Correlation between the p-p65-positive neuron population level and the motor 
neurological behavior score in PHP.B-GFP- or PHP.B-TRIM9-infected aged mice 24 hr after 
30-min MCAO.
Data in (B), (D), (F), (H), (I), (K), (M), and (N) are shown as mean ± SD.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-IκBα Cell Signaling Technology Cat #9247
Rabbit monoclonal anti-pIκBα Cell Signaling Technology Cat #2859
Rabbit monoclonal anti-p-p65 Cell Signaling Technology Cat #3033
Mouse monoclonal anti-β-actin Santa Cruz Cat #sc-47778
Rabbit polyclonal anti-TRIM9 Stephanie L. Gupton lab N/A
Mouse monoclonal anti-ubiquitin Santa Cruz Cat #sc-8017
Rabbit monoclonal anti-β-TrCP Cell Signaling Technology Cat #4394
Mouse monoclonal anti-HA Santa Cruz Cat #sc-57594
Mouse monoclonal anti-GFP Santa Cruz Cat #sc-101525
Mouse monoclonal anti-Flag Sigma Cat #F1804
Mouse monoclonal anti-GFAP Cell Signaling Technology Cat #3670
Rabbit monoclonal anti-lba1 Abeam Cat #ab178846
Rabbit polyclonal anti-NeuN Millipore Cat #ABN78
Mouse monoclonal anti-SMI312 Abeam Cat #ab24574
Rabbit polyclonal anti-NG2 Abeam Cat #ab83178
Mouse monoclonal anti-Olig2 Millipore Cat #MABN50
Rat monoclonal anti-IL6 Thermo Cat #AMC0864
Mouse monoclonal anti-NeuN Millipore Cat #MAB377
Rabbit polyclonal anti-CCL2 Abeam Cat #9779
Mouse monoclonal anti-MAP2 Abeam Cat #ab11267
Rat anti-CD45 BD PharMingen Cat #103116
Rat anti-CD11b eBioscience Cat #48-0112-82
Rat anti-GR1 BD PharMingen Cat #108412
Rat anti-CD3e BD PharMingen Cat #100328
Rat anti-CD11c BD PharMingen Cat #117318
Chemicals, Peptides, and Recombinant Proteins
Protease inhibitor cocktail Roche Cat #4693159001
Phosphatase inhibitor PhosSTOP Roche Cat #4906845001
Recombinant mouse TNF-α Biolegend Cat #575202
Recombinant mouse IL-1β Biolegend Cat #575102
MG132 R&D Systems Cat #1748
Critical Commercial Assays
RNeasy Mini Kit QIAGEN Cat #74104
KAPA stranded mRNA-seq Kit KAPA Biosystems Cat #kk8421
iScript cDNA Synthesis Kit Bio-Rad Cat #1708891
iQ SYBR Green supermix Bio-Rad Cat #1708880
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REAGENT or RESOURCE SOURCE IDENTIFIER
RNAscope 2.5 HD Reagent Kit-RED Advanced Cell Diognostics Cat #322360
Cresyl Echt Violet Staining Kit American MasterTech Cat #AHC0443
In Situ Cell Death Detection Kit Roche Cat #11684795910
In Situ Cell Death Detection Kit Roche Cat #12156792910
Mouse IL-6 ELISA Kit BD Biosciences Cat #555240
Mouse IL-1β ELISA Kit BD Biosciences Cat #559603
Mouse TNF-α ELISA Kit BD Biosciences Cat #555268
Mouse IL-10 ELISA Kit BD Biosciences Cat #555252
Neural Tissue Dissociation Kit MACA Miltenyl Biotec Cat #130093231
BCA Protein Assay Kit Thermo Fisher Scientific Cat #23227
Lipofectamine 2000 Transfection Kit Thermo Fisher Scientific Cat #11668027
Lipofectamine RNAiMAX Kit Thermo Fisher Scientific Cat #13778075
LIVE-DEAD Viiability /Cytotoxicity Kit Thermo Fisher Scientific Cat #L3224
Propidium iodide Invitrogen Cat #P3566
Deposited Data
RNA-seq data This paper GEO: GSE114652
Experimental Models: Cell Lines
HEK293T ATCC Cat #CRL-11268
Trim9-knockout neurons This paper N/A
7r/m9-knockout MEFs This paper N/A
Trim9-derived neurons This paper N/A
Experimental Models: Organisms/Strains
C57BL/6J mice The Jackson Laboratory JAX stock 000664
Trim9 deficient (Trim9+/−) mice Stephanie L Gupton lab N/A
Oligonuoleotides
Primers for RT-qPCR (See Table S3) N/A
RNAscope Probe: Murine Trim9-specific probe Advanced Cell Diagnostics Cat #479071
Recombinant DNA
Plasmid: pCDH-HA-Trim9 This paper N/A
Plasmid: pCDH-HA-Trim9-SA This paper N/A
Plasmid: AAV-PHP.B vector Viviana Gradinaru lab N/A
Plasmid: AAV-PHP.B:CAG-GFP This paper N/A
Plasmid: AAV-PHP.B:CAG-Trim9 This paper N/A
Plasmid: AAV-PHP.B:CAG-Trim9-SA This paper N/A
Software and Algorithms
GraphPad Prism v6.03 GraphPad Software https://www.graphpad.com/
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